Short‐chain acyl post‐translational modifications in cancers: Mechanisms, roles, and therapeutic implications
Cancer Communications · 2025-10 · 45 (10) · 1247-1284
DOI: 10.1002/cac2.70048 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Communications, online erschienen am 24.07.2025. Verfasst von Ting Wu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, P. R. China. Hauptthemen laut MEDLINE: Protein Processing, Post-Translational, Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Innovation Team Project of China Medical University, Beijing Xisike Clinical Oncology Research Foundation.
Abstract (Originalsprache)
Post‐translational modifications (PTMs) play a pivotal role in epigenetic regulation and are key pathways for modulating protein functionality. PTMs involve the covalent attachment of distinct chemical groups, such as succinyl, crotonyl, and lactyl, at specific protein sites, which alter protein structure, function, stability, and activity, ultimately influencing biological processes. Recently, metabolically derived short‐chain acylation modifications (with acyl groups containing fewer than six carbon atoms) have been progressively identified, such as butyrylation, succinylation, crotonylation, and lactylation, differing from traditional acetylation in structure, physicochemical properties, function, and regulation. Aberrant short‐chain acyl‐PTMs are often associated with tumorigenesis. Research highlights that PTMs like succinylation and lactylation are essential in regulating tumor metabolism, drug resistance, and immune responses. This review elucidates the regulatory mechanisms of eight short‐chain acyl‐PTMs—butyrylation, succinylation, crotonylation, malonylation, glutarylation, 2‐hydroxyisobutyrylation, β‐hydroxybutyrylation, and lactylation—that are involved in tumor initiation and progression. Their roles in controlling tumor genomic stability, gene transcription, protein stability, enzyme activity, and nuclear localization are summarized, demonstrating their impact on related biological processes such as tumor metabolism, multi‐drug resistance, and immune evasion. Additionally, the review provides an overview of current drug research targeting enzymes that regulate PTMs, offering critical insights to advance therapeutic strategies for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, P. R. China.
- Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment o…
- Department of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
- Medical Oncology Department of Gastrointestinal Cancer, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. Ch…
- Department of Anorectal Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
- Scientific Experimental Center, School of Pharmacy, China Medical University, Shenyang, Liaoning, P. R. China.
ORCID-Profile: Ting Wu
Förderung
- National Natural Science Foundation of China
- Science and Technology Innovation Team Project of China Medical University
- Beijing Xisike Clinical Oncology Research Foundation
- China Postdoctoral Science Foundation
- Liaoning Province Natural Science Foundation Joint Fund
- Doctoral Start-up Foundation of Liaoning Province
Zitieren
APA
Wu, T., Zhao, Y., Zhang, X., Wang, Y., Chen, Q., Zhang, M., Sheng, H., Zhang, Y., Guo, J., Li, J., Fan, Y., Wang, Z., Li, Y., Wang, H., Wei, M., Hu, X., & Wu, H. (2025). Short‐chain acyl post‐translational modifications in cancers: Mechanisms, roles, and therapeutic implications. Cancer Communications, 45(10), 1247-1284. https://doi.org/10.1002/cac2.70048
Vancouver
Wu T, Zhao Y, Zhang X, Wang Y, Chen Q, Zhang M, et al. Short‐chain acyl post‐translational modifications in cancers: Mechanisms, roles, and therapeutic implications. Cancer Communications. 2025;45(10):1247-1284. doi:10.1002/cac2.70048
BibTeX
@article{Wu2025,
author = {Wu, Ting and Zhao, Yingqi and Zhang, Xin and Wang, Yuanhe and Chen, Qiuchen and Zhang, Mingrong and Sheng, Huan and Zhang, Yuying and Guo, Jinyu and Li, Jun and Fan, Yuxuan and Wang, Ziqing and Li, Yalun and Wang, Haoran and Wei, Minjie and Hu, Xiaoyun and Wu, Huizhe},
title = {Short‐chain acyl post‐translational modifications in cancers: Mechanisms, roles, and therapeutic implications},
journal = {Cancer Communications},
year = {2025},
volume = {45},
number = {10},
pages = {1247--1284},
doi = {10.1002/cac2.70048}
}
EUVIMED